LakeShore Biopharma
LSB was delisted on the 19th of September, 2025.
9 hedge funds and large institutions have $1.01M invested in LakeShore Biopharma in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 0 closing their positions.
50% more funds holding
Funds holding: 6 → 9 (+3)
5.55% more ownership
Funds ownership: 2.04% → 7.59% (+5.6%)
24% less capital invested
Capital invested by funds: $1.34M → $1.01M (-$328K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$2.59M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$26.2K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$693 |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$148 |
Top Sellers
LSB Hedge Fund Activity: Q1 2025 in Review
9 of the 7,473 institutional investors tracked by Wall St. Rank reported a position in LakeShore Biopharma (LSB) for Q1 2025, worth a combined $1.01M — down 24% from $1.34M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new LSB positions and 0 closed out — a net gain of 3 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Toronto Dominion Bank, opening a new position worth an estimated $2.59M.
- 9 institutional investors held LakeShore Biopharma (LSB) as of Q1 2025, up from 6 in Q4 2024.
- Funds reported $1.01M of LakeShore Biopharma stock for Q1 2025, down 24% quarter-over-quarter.
- 3 funds opened new LakeShore Biopharma positions in Q1 2025 and 0 closed out, a net change of +3 holders.
- The largest LakeShore Biopharma buyer in Q1 2025 was Toronto Dominion Bank, an estimated $2.59M added.
Based on aggregated 13F filings for Q1 2025.